CB Insights / patent data · Jan 2025
Clear Gene’s cancer-biomarker patent was shown as granted on Apr. 15, 2025, indicating continued IP development around residual breast cancer detection.
Our tests help eradicate cancer by telling doctors whether they got…
Public company, workplace, funding, and market signals
Founders
Founder / CEO
Investors
38 jobs at Clear Gene
CB Insights / patent data · Jan 2025
Clear Gene’s cancer-biomarker patent was shown as granted on Apr. 15, 2025, indicating continued IP development around residual breast cancer detection.
LinkedIn post by Brandon Steelman · Jun 2020
Brandon Steelman said Clear Gene was selected by the NIH RADx initiative to scale national COVID testing, a major validation/milestone during the pandemic.
Patent application record · Jun 2020
Patent application covering RNA/gene-expression-based analysis of residual disease and surgical-margin testing, reflecting the company’s core diagnostic platform.